Archive for September, 2020

$WTER 420 with CNW – The Next Big Trend in Cannabis: Low-THC Products

For many years, the most popular and well known cannabinoid was THC. However, in the recent times, there has been an increase in CBD awareness and popularity.

Search trends on Google indicate that CBD is searched more often as compared to THC, and this has been the case for the last few years. Clearly, interest in CBD is on the rise, but is its use increasing too? Many wonder if CBD products will lead to a decline in THC popularity among patients and consumers. Will that be the case? Below are some reasons why CBD might just eclipse THC in the consumption department.

CBD products are easier to cultivate

CBD products are also referred to as low-THC products. Marijuana strains that are low in THC are more common in nature than strains that are high in THC. To get a plant to yield high amounts of THC, you require the right ecosystem and environment.

This is in comparison to hemp with low THC which can grow anywhere, as long as the temperatures are not extremely cold or hot. Additionally, low THC products can be locally sourced, making them easier to get to international markets.

This makes low THC varieties of marijuana easier to cultivate unlike high THC varieties, which boosts their popularity with consumers.

There are more favorable laws governing CBD

Most low-THC products that are internationally available are derived from hemp and in many countries, the regulations and laws of hemp are generally more favorable as compared to non-hemp cannabis varieties. A great example of a country with favorable laws would be Switzerland.

In Switzerland, floral hemp or low-THC marijuana, is very popular and widely available for legal purchase by adults. While products that have more than 1% THC in them are prohibited for recreational use, marijuana products that have less than 1% THC are legal in the country.

History has shown that a country is less likely to pass a high-THC recreational law but will have no qualms with approving a low-THC medical marijuana law. This also affects consumer popularity.

Reduces the use of prescription medication

A recent study discovered that the increased availability of low-THC marijuana products led to a decrease in the use of pharmaceutical drugs. This is not only good for marijuana consumers but also for the society as a whole, as there’s a decrease in public-entitlement health-related costs.

This just goes to show that as the fight to have plant-based therapies recognized as an alternative form of treatment, many are finding ways to incorporate low-THC marijuana remedies into their routines, showing that there is a growing trend of these products capturing a bigger market share. What do companies like The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) think about this growing trend?

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Wednesday, September 30th, 2020 Uncategorized Comments Off on $WTER 420 with CNW – The Next Big Trend in Cannabis: Low-THC Products

$POAI Sufficient Vitamin D Levels May Reduce Coronavirus Complications, Death

Researchers have discovered that coronavirus patients who were hospitalized and had vitamin D sufficiency were at a significantly lower risk of experiencing hypoxia, becoming unconscious or dying. Additionally, they had high levels of lymphocytes, which are immune cells that help the body fight infections, and had low levels of the C-reactive protein, which is an inflammatory marker.

The study was authored by Michael F. Holick, who is a professor of physiology, medicine and molecular medicine and biophysics at Boston University School of Medicine. The professor explained that the study provided evidence showing that sufficient levels of vitamin D reduced COVID-19 complications, such as the release of too many cytokines into the patient’s blood rapidly (cytokine storm) and death.

The study involved 235 patients admitted to the hospital with coronavirus from whom blood samples were collected. The samples were used to measure the vitamin D levels of the patients as well as analyze lymphocyte numbers and C-reactive protein.  The patients were then observed for any developments in their symptoms such as unconsciousness, and difficulty breathing that caused hypoxia and ultimately, death. The scientists then compared this data in patients who had sufficient vitamin D levels to those that suffered from its deficiency.

In patients who were more than 40 years old and vitamin D sufficient, the researchers found that they were 51.5% less likely to die from an infection in comparison with the patients who were vitamin D insufficient or deficient.

In another study that was recently published by Holick, they discovered that being vitamin D sufficient can decrease the contraction risk of COVID-19 by 54%. The researchers also believe that having vitamin D sufficiency can help the body fight the coronavirus as well as other viruses that cause upper respiratory tract infections, such as influenza. He added that there was still concern that the fusion of a coronavirus infection and an influenza infection may increase hospitalizations considerably as well as death, which may occur as a result of adverse effects from these viral infections.

Holick states that the study gives a cost-effective and simple plan to improve an individual’s ability to fight COVID-19 and decrease the coronavirus’ adverse outcomes like a patient being hooked up to a ventilator or an immune response that leads to a cytokine storm or death. Furthermore, he adds that it’s only prudent for individuals to take vitamin D supplements, especially since vitamin D insufficiency and deficiency is so common among both adults and children. This, he says, may help decrease the risk of infection or experiencing complications from the coronavirus.

This discovery that vitamin D levels can affect the extent to which one is affected by COVID-19 may be of interest to biomedical entities like Predictive Oncology (NASDAQ: POAI) since it strengthens the hypothesis that nearly all disease conditions are linked to a nutritional deficiency.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, September 30th, 2020 Uncategorized Comments Off on $POAI Sufficient Vitamin D Levels May Reduce Coronavirus Complications, Death

$BHAT Enters Updated LOI to Acquire 51% of Mobile Game Developer Csfctech

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced its entry into an updated letter of intent (“LOI”). Under the terms of the LOI, BHAT will acquire the control of 51% of Fuzhou Csfctech Co. Ltd. (“Csfctech”) and its two subsidiaries through the direct acquisition of 51% of the outstanding shares of its offshore holding company. Csfctech is a developer and distributor of mobile games with an international user base across Mainland China, Japan, Taiwan, the United Arab Emirates and Africa. “We believe that this transaction represents a significant development in our strategy and ability to rollout a wider breath of augmented reality and mobile games to our growing audience in China,” BHAT CEO Xiaodong Chen said in the news release. “Csfctech’s business covers more than 100 games available on a number of different platforms and maintains a strong following of customers based in Asia and Africa. Through this acquisition, not only can we integrate the product development technology, operation and distribution resources of Csfctech, but also our combined resources may help strengthen the available distribution channels. In addition, we expect to leverage our combined expertise to improve the product structure and enhance the overall revenue scale and marketing capabilities.”

Click here to view the full press release

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile-game features. The company’s entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the company’s investor relations website at www.IR.BlueHatGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Wednesday, September 30th, 2020 Uncategorized Comments Off on $BHAT Enters Updated LOI to Acquire 51% of Mobile Game Developer Csfctech

$CRTD Appoints New COO to Lead Growth Strategy, Manage Partnership Initiatives

Creatd (NASDAQ: CRTD, CRTDW), the parent company and creator of the Vocal platform, today announced the appointment of Laurie Weisberg as its new chief operating officer. Weisberg currently sits on Creatd’s board of directors and will lead the company’s sales team in the execution of its growth strategy and manage all strategic partnership initiatives. This appointment aligns with Creatd’s 2021 plans to broaden and scale its product line and revenues, including Vocal for Brands, Seller’s Choice, and Vocal+ paid subscriptions. “I have closely observed the Creatd team over the last year, particularly since I assumed my role as a member of the board of directors over the summer,” said Weisberg in the news release. “It is clear that the team’s ability to unleash the power of the network in delivering valuable content for audiences, while at the same time helping brands drive their growth by leveraging the highly engaged Vocal community and rich first-party data, makes Creatd a unique brand with a global proposition. As COO, I look forward to working closely with Jeremy and the rest of the management team to continue to build Creatd’s scalable and profitable business lines.”

To view the full press release, visit http://nnw.fm/VEJRC

About Creatd Inc.

Creatd, the parent company and creator of the Vocal platform, empowers content creators and brands through technology and data-driven innovation. Creatd identifies opportunities within the digital platform and content monetization space, and leverages them through the company’s proprietary Vocal technology, as well as through complementary digital businesses including Vocal for Brands and Seller’s Choice. Since launching in 2016, Vocal has become home to over 700,000 content creators and brands of all shapes and sizes, attracting audiences across its network of wholly owned and operated communities. For more information about Creatd and its Vocal platform, visit www.Creatd.com and www.Vocal.media.

NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://nnw.fm/CRTD

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Wednesday, September 30th, 2020 Uncategorized Comments Off on $CRTD Appoints New COO to Lead Growth Strategy, Manage Partnership Initiatives

$CNSP Study Discovers That Septic Shock Begins Earlier than Scientists Thought

Researchers from Johns Hopkins University have discovered that septic shock can be classified into four categories, making it easier for hospitals to accurately triage sepsis patients and treat individuals who are at higher risk first. This will prevent a higher mortality rate from people dying due to this costly and deadly medical condition.

The leading causes of in-hospital deaths are septic shock and sepsis. Biomedical researchers from the Johns Hopkins School of Medicine and Whiting School of Engineering state that their findings may be used to detect early signs of septic shock in patients who are rapidly developing the infection as it overpowers their immune system. Septic shock in fatal cases can lead to organ failure and eventually, death.

This new study from the Institute of Computational Medicine and the Department of Biomedical Engineering also shows that septic shock starts much earlier than health practitioners currently understand. The findings from the study will help in answering a lot of the questions that surround this deadly disease, although we may have to wait a bit longer for an algorithmic definition to be discovered.

The lead author of the study and doctoral student in biomedical engineering, Ran Liu, said that they used patients’ risk categories to group them. This demonstrated the usefulness of having various risk categories that would indicate the severity of septic shock cases in patients. Their research was supervised by Raimond L. Winslow, who is Liu’s adviser and also the director of the Institute for Computational Medicine. Additionally, the research was published on eLife.

The study, which used more than 24 physiological indicators, collected from 200,000 individual admissions from various hospitals in the U.S., discovered that the increase in risk of an individual to suffer from septic shock occurred within half an hour to an hour after the first sign of shock registers.

The descent into septic shock registers as rapid shifts in lactate levels, heart rate and blood pressure. When a patient’s immune system is overpowered by an infection, the body starts to lose the ability to stop the body from deteriorating further. The scientists believe that this is when septic shock begins and refer to this period as “pre-shock.”

The study states that when a patient enters the pre-shock stage, they are already in a state of septic shock. Patients who have been categorized in the highest risk of experiencing septic shock are in a septic shock stage for at least 10 hours before they can satisfy what is the current clinical definition of septic shock.

The paper adds that the plummet into pre-shock is quite rapid and that the use of intelligent and automated monitors may help detect it in patients. The researchers recommend that hospitals begin implementing automated technology to help detect these early warnings. Furthermore, the study supports the existing research that requires lactate measurements be done every 1- 2 hours for better categorization of patients, stating that their research calculates median time between lactate observations to be 11.2 hours.

Septic shock is a serious condition, and there is no doubt that biomed companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) welcome the additional information that this research has unveiled about this condition.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, September 30th, 2020 Uncategorized Comments Off on $CNSP Study Discovers That Septic Shock Begins Earlier than Scientists Thought

$SRAX Acquires LD Micro, Accelerates Adoption of SaaS Data Management Platform

  • SRAX recently closed acquisition of LD Micro, leading micro-cap information portal
  • LD Micro to become wholly-owned subsidiary of SRAX for 1.6 million in common stock plus $4 million cash
  • Acquisition to accelerate adoption of Sequire, SRAX’s SaaS investment analytics platform
  • Sequire revenue grew 29% year-over-year for Q2 2020, user base doubled to one million users during Q3 2020

SRAX (NASDAQ: SRAX), a data-based financial technology company, recently closed the acquisition of LD Micro, a leading data portal serving the small and micro-cap space. The deal, worth 1,600,000 shares of common stock and $4 million in cash, will make LD Micro a wholly-owned subsidiary of SRAX while maintaining founder Christopher Lahiji as president and appointing him to SRAX’s board of directors.

The move comes during a rapid growth period for Sequire, SRAX’s data analytics SaaS platform. Geared towards the investment industry, Sequire unlocks data and insight for public companies that can be used to activate marketing campaigns to engage both new, existing and potential investors.

Prior to acquiring LD Micro, SRAX had witnessed strong early success with Sequire. The platform doubled its user base to over one million investors and traders in two months (http://nnw.fm/JRZtk), in addition to posting Q2 earnings that showed a 29% increase in year-over-year revenue. The acquisition of LD Micro – a leading brand in the provision of exclusive information on micro-cap North American stocks – is expected to accelerate the adoption of Sequire while enhancing LD Micro’s own digital assets.

Sequire helps public companies gain insights on the activities of both retail and institutional investors, providing critical actionable data to activate successful campaigns aimed to increase engagement with current investors while attracting new ones. Sequire’s application suite is currently being used by over 91 companies to harness the power of their data through the use of tools that leverage investor intelligence and outreach, track warrants, engage users through surveys, and promote events and roadshows.

“The platform is an absolute game-changer for public companies and their shareholders,” said LD Micro founder Chris Lahiji in recent statements  (http://nnw.fm/ppRfl). “Both companies believe that one day executives will rely on Sequire the same way investors rely on Bloomberg.”

“Over 1,500 companies have presented at LD Micro’s events since 2008, and almost all of them would be immediate beneficiaries of this technology,” he continued.

The acquisition of LD Micro is expected to be immediately accreditive to SRAX’s operations. The recent LD 500 conference, held online in early September, included presentations from hundreds of companies across a wide range of industries in addition to featuring keynotes with some of the most prominent figures in the micro-cap world.

The company continues to leverage the growing demand for quantifiable and detailed consumer data by creating specialized tools that empower companies to reveal core consumers and their characteristics across a wide range of industries.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Tuesday, September 29th, 2020 Uncategorized Comments Off on $SRAX Acquires LD Micro, Accelerates Adoption of SaaS Data Management Platform

$SGLB Announces Contract, Plans to Begin Production Deployment of PrintRite3D Software

Sigma Labs (NASDAQ: SGLB), a leading developer of in-process, quality-assurance software for the commercial 3D-printing industry, has been awarded a contract by a leading global energy technology provider. The contract, which was finalized after a successful Rapid Test and Evaluation (“RTE”) program, calls for beginning production deployment of PrintRite3D(R) in-process quality assurance software. During the RTE, engineers worked closely with Sigma’s engineering team to evaluate issues involved in the customer’s application of SGLB’s proprietary PrintRite3D technology, specifically as it pertained to running the technology on an EOS single-laser machine and an SLM dual-laser machine. The announcement of this contract follow SGLB’s recent sale of an initial PrintRite3D production system to Mitsubishi Heavy Industries. “The conversion from our RTE program to beginning production deployment is a testament to the traction our enabling technology is garnering in the additive manufacturing industry,” Sigma Labs CEO Mark Ruport stated in the press release.

To view the full press release, visit http://nnw.fm/oOwHD

About Sigma Labs Inc.

Sigma Labs is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of 3D metal printing For more information about the company, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Tuesday, September 29th, 2020 Uncategorized Comments Off on $SGLB Announces Contract, Plans to Begin Production Deployment of PrintRite3D Software

$POAI Set to Capitalize on Increased AI Usage within Oncological Treatments

  • Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients
  • Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients
  • POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid clinical decision-making and lead to better health outcomes. The National Cancer Institute (“NCI”) in the United States has separately revealed that it is increasingly looking to invest in supporting research and developing infrastructure centered around the usage of AI in developing oncological treatments (https://ibn.fm/BFD5m) – a niche where Predictive Oncology is increasingly building a dominant presence. In addition, the White House has announced $2 billion funding for public and private sector “AI hubs” designed to drive key advances in AI as well as other computational technologies (https://ibn.fm/kcgSH).

A primary goal of precision cancer medicine is the accurate prediction of optimal drug therapies based upon the personalized molecular profiles of patient tumors; ideally, such predictions are based upon well-established molecular cause-and-effect relationships that are disrupted in cancer calls (https://ibn.fm/LQvQX). The foundation of these accurate predictions is built upon extensive bodies of data, with the volume of cancer-relevant data being generated and electronically stored on a daily basis vastly exceeding what could even be imagined only a few decades ago. As such, the search for significant correlations within cancer-relevant “big” datasets is a task which is ideally suited for artificial intelligence and machine learning-based approaches.

Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its unique real-world longitudinal data of drug-response and genomic profiles gathered from more than 150,000 de-identified cancer cases. Through its subsidiary Helomics, POAI is seeking to bring this cutting-edge technology to cancer research, where it is working with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how tumors respond to drugs, which can be used both for clinical decision support and research into new therapies.

Meanwhile, the company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians in identifying which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ proprietary Oncology Capture Technology Platform, which is able to grow the patient’s heterogeneous tumor sample in the laboratory, enabling oncologists to develop a patient-specific treatment plan (https://ibn.fm/byGJI).

Going forward, the use of artificial intelligence will help oncological researchers quickly understand how cancer cells become resistant to anti-cancer drugs, which can help improve drug development and adjust drug use. The technology can also be used to manage the use of chemotherapy drugs and predict a patient’s tolerance levels, thus allowing for chemotherapy regimens to be optimized. In the future, by leveraging Predictive Oncology’s AI-driven solutions, doctors will be able to make better-informed treatment decisions, thus reducing the need for unnecessary or poorly targeted treatments and improving patient outcomes.

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, September 29th, 2020 Uncategorized Comments Off on $POAI Set to Capitalize on Increased AI Usage within Oncological Treatments

$NETE California Governor Promotes Switch to Electric Vehicles

It’s becoming increasingly difficult to bury our heads in the sand in regard to climate change. The earth is hurtling towards a ‘hothouse’ state not seen in 50 million years and a lot of the blame lies at the feet of humanity. Perhaps the most obvious sign of climate change is that it’s getting hotter and according to scientists, the next three years might be even hotter than normal. No state has experienced the heat as much as California; five of the largest wildfires in state history have been ignited in recent weeks, and residents have become accustomed to rolling blackouts due to heat waves.

In a bid to reduce their carbon footprint, plenty of governments have launched programs to phase out internal combustion-engine vehicles in exchange for electric vehicles (“EVs”) that run on clean, renewable energy and produce zero emissions. Similarly, California Governor Gavin Newsom has already set the goal of 100% zero-emission energy sources for the state’s electricity by 2045. He signed the bill mandating the electricity target in 2018 as well as an executive order calling for statewide carbon neutrality.

His latest effort at reducing greenhouse gas emissions came on Wednesday when Newsom pledged to ban all sales of new gasoline-powered vehicles by 2035. The order won’t prevent Californians from owning or selling gasoline or diesel-powered vehicles on the used-vehicle market, rather it will prevent the sale of new carbon energy-powered vehicles. This pledge makes California the first state in the country to ban conventional vehicles alongside 15 other countries including France and Germany.

The move was met with resistance from White House spokesman Judd Deere who claimed it was another example of “how extreme the left has become,” concluding that “the lengths to which they will go to destroy jobs and raise costs for the consumer is alarming.” However, Governor Newsom disagrees, arguing that the Trump administration’s argument is “stale” and inaccurate. “This is where the automobile manufacturers are going,” he says. “We want to accelerate a trend you’re seeing all around the rest of the world.”

He states that the plan is absolutely doable based on the state’s infrastructure. “We can do it. I mean, the reality is we’re already doing it. Thirty-four percent of our electricity comes from renewable places. We have over 50% of all the electricity produced and procured in California from non-carbon sources. We have a plan. We have a strategy,” he says. On the Trump administration’s claim that switching to green energy will devastate the job economy, Newsom says that it is not factual.

“It’s gobbledygook. It’s nonsense. It’s not factual. It’s not even an interesting argument. It’s rather stale. Already, California has five times more green jobs than we do fossil fuel jobs. Fossil fuels are really the alternative energy.”

Analysts say such steadfastness as displayed by Gov. Newsom attracts the admiration of companies like Net Element (NASDAQ: NETE) that would like carbon emissions to be brought to a halt in all major economies and around the world.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Tuesday, September 29th, 2020 Uncategorized Comments Off on $NETE California Governor Promotes Switch to Electric Vehicles

$DRIO Researchers Develop Simple Way to Detect Coronavirus Antibodies Using Glucose Monitors

Three scientists from Johns Hopkins; a biomedical engineer, a pharmacologist and a biophysicist, have come together to build a device that can detect if an individual has SARS-CoV-2 antibodies, which is the virus that causes COVID-19. Antibodies are small proteins produced by the immune system to help your body counteract a viral encounter and provide the immunity to fight it off if future infections occur.

The researchers derived their inspiration from a glucose monitor, which is used by millions of people around the world. This, they said, could help them design an antibody detector that can be used easily and is affordable worldwide.

People who suffer from diabetes use glucose monitors to measure their blood sugar levels. This is done by pricking their finger for a drop of blood which is then placed on a test strip paper and inserted into the monitor.

The three researchers; Jamie Spangler, assistant professor of biomedical engineering, Netz Arroyo, assistant professor of pharmacology and molecular sciences, Taekjip Ha, professor of biophysics, biophysical chemistry and biomedical engineering say that this gadget can also be re-engineered to detect the presence of glucose in chemical reactions that occur as a result of antibodies in the blood.

To do this, the team developed a test strip which contained spike protein obtained from the SARS-CoV-2 virus surface. Then they added a drop of blood from a patient and observed as the COVID-19 antibodies that were present in the blood bind with the spike proteins on the test strip. After this, the scientists dipped the test strip into a tube which contains an enzyme that binds itself to the coronavirus antibodies.

The next step was to wash off the excess enzyme and insert the strip into a solution that contained a molecule that the enzyme transforms into glucose. Finally, they used a glucose monitor to read the amount of glucose that is present on the strip, which is a substitute for coronavirus antibodies present in the blood sample from the patient.

Arroyo stated that working on the project had been a good opportunity to learn from his colleagues, engage with them and brainstorm together to generate a creative solution that addressed a crucial need that was brought forth by the coronavirus pandemic. He added that they were looking into developing a bio sensing platform that would help monitor infection spread better for both the current crisis as well as for any that might occur in the future.

The research is still ongoing, and the scientists are running more tests on the patent-pending technology. Analysts say biomed sector players like DarioHealth Corp. (NASDAQ: DRIO) are pleased so many innovators rising up to the challenge of the ongoing pandemic.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, September 29th, 2020 Uncategorized Comments Off on $DRIO Researchers Develop Simple Way to Detect Coronavirus Antibodies Using Glucose Monitors

$CNSP Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.

  • Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020
  • CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers
  • Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has expanded its Scientific Advisory Board by welcoming new member Dr. Patrick Wen, M.D., a leading neurology and neuro-oncology expert (https://ibn.fm/VJ6e9). Dr. Wen joins current Board members, Dr. Waldemar Priebe, Ph.D., and Dr. Sigmund Hsu, M.D., both of whom were involved in the Phase 1 trial of Berubicin, CNS Pharmaceuticals’ lead drug candidate.

Dr. Wen is a Neurology professor at Harvard Medical School and the Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute. Dr. Wen is a member of the Board of Directors of The Society for Neuro-Oncology and is also its immediate past President. An accomplished neuro-oncologist with a proven track record treating brain tumors and related neurologic complications, Dr. Wen is a graduate of University of London’s Medical College of St. Bartholomew’s Hospital. He continued his postgraduate internal medicine training with the University of London and completed his neurology residency with the Harvard-Longwood Neurology Training Program.

According to CNS Pharmaceuticals CEO John Climaco, Dr. Wen’s extensive experience in neuro-oncology will be invaluable to the company as it prepares for its upcoming Berubicin clinical trials. “The addition of Dr. Wen strongly complements our strategy to further drive the development of Berubicin as we look forward to initiating our pivotal Phase II trial in the U.S. and to working with our partner WPD Pharmaceuticals on the Phase I pediatric and Phase II adult studies in Poland,” Climaco added.

Dr. Wen’s appointment was included among the latest company updates furnished to the Securities and Exchange Commission on September 21, 2020. The investor presentation in the Form 8-K/A also announced that the company’s pivotal Phase 2 clinical trial for Berubicin in the United States is expected to begin in Q1 2021 (https://ibn.fm/MRaIq). In addition, Berubicin clinical trials in Poland (Phase 2 for adults and the first-ever Phase 1 trial for pediatric patients) are also due to begin on a similar timeline.

CNS Pharmaceuticals’ lead drug candidate is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. It is an organ targeted therapeutic that belongs to a class of cancer drugs called anthracyclines. CNS Pharmaceuticals has stated that it believes, based on limited clinical data, that Berubicin is the first drug in this class to cross the blood-brain barrier in adults, reaching the tumor cells of a patient with brain cancer.

Berubicin was developed by CNS Founder and Scientific Advisory Board member Dr. Waldemar Priebe, Ph.D., Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. The development of Berubicin has been ongoing for over 15 years. The drug was granted Orphan Drug designation by the FDA for malignant gliomas in June 2020. CNS Pharmaceuticals is currently expected to make an Investigational New Drug (“IND”) submission to the FDA in Q4 2020.

In Phase 1 trials of Berubicin, conducted by Reata Pharmaceuticals (NASDAQ: RETA), 44% of GBM patients showed clinically significant response to Berubicin. A patient from the Phase 1 trial remains cancer-free following the trial treatment of Berubicin approximately 14 years ago.

CNS Pharmaceuticals plans for the Phase 2 adult trial in the United States to be adaptive, randomized, and controlled. These criteria for Phase 2 are intended to provide the data required for accelerated approval by the FDA. Additionally, the company plans to use the Phase 2 adult trial in Poland, conducted by sub-licensee WPD Pharmaceuticals, Inc. (CSE: WBIO) (FSE: 8SV1), to provide additional statistical support for the U.S. trial.

Plans are also in motion to begin Berubicin clinical trials for lymphomas, pancreatic, and ovarian cancers in 2021, which speaks to the high level of confidence CNS Pharmaceuticals has in Berubicin trials and its potential impact on the brain tumor therapeutics market. It is estimated that the global brain tumor therapeutics market will reach $3.4 billion by 2025, growing at a CAGR of 7.2 percent (https://ibn.fm/qJSuy).

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, September 29th, 2020 Uncategorized Comments Off on $CNSP Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.

$WTER 420 with CNW – Vermont Marijuana Policy Reform Bills Sent to Governor’s Desk

A proposal to legalize cannabis sales in Vermont and another one that provides automatic expungements for marijuana convictions have been pushed to the governor’s desk after a final Senate vote was conducted on Tuesday.

The state Senate approved the negotiated legislation with a 23-6 vote after the House of Representatives had approved it.

In 2018, Vermont legalized the cultivation of 2 marijuana plants and possession of a maximum of 29 grams of marijuana. However, no regulations that allow retail sales were put in place.

The governor of Vermont, Gov. Philip Brian Scott (R) has yet to explicitly confirm or deny whether he will put his signature on the S.54 measure but he admitted to being impressed last week on how the measure was received in the legislative process and noted that he would take that into account.

Apart from the marijuana sales legalization bill, the Senate also approved a separate bill that will issue automatic expungements of cannabis convictions as well as allow individuals to possess and grow more marijuana without being arrested. The House had passed the proposal earlier this month, meaning it’s also headed to the governor’s desk as well.

The proposed marijuana sales bill states that cannabis would be subject to the state’s 6% sales tax and an additional 14% excise tax. S.54 also highlights a few social equity provisions like helping individuals who have been adversely affected by the drug war and making cannabis business licenses for minorities a priority. Additionally, an independent regulatory commission will be in charge of promoting small business participation in the market.

A cannabis control commission would be established and would be responsible for the issuance of licenses to growers, retailers, manufacturers, labs and wholesalers. This body will also assume the role of the Department of Public Safety in regulating the state’s medical marijuana industry.

Additionally, flavored vape cartridges would be banned and a 30% THC limit would be imposed on marijuana flower while marijuana oil may only contain at most 60% THC.

A fiscal analysis that was done on the final bill shows that Vermont will generate roughly $13.3 million – $24.2 million in annual marijuana tax revenue by the Fiscal Year 2025. The Joint Fiscal Office estimates that licensing fees may generate an additional $650,000 in revenue each year. Municipalities that have cannabis businesses will also be allowed to impose additional local fees.

Industry watchers say sector players like The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) will be hoping that the governor puts the wishes of the people into consideration while deciding whether to enact or reject the marijuana policy reform bills before him.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Monday, September 28th, 2020 Uncategorized Comments Off on $WTER 420 with CNW – Vermont Marijuana Policy Reform Bills Sent to Governor’s Desk

$WTER Featured in Exclusive Broadcast

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced that it was featured in a broadcast titled, “New Opportunities Abound for Specialty Beverage, Water Companies.” The piece highlights significant M&A potential for smaller specialty brands and reads, “Companies such as The Alkaline Water Company, one of the fastest-growing enhanced water companies in the industry, could be an attractive option. . . . Alkaline88 remains one of the top-selling brands in the value-added water category. According to recent trade data, Alkaline88 reported double-digit growth despite the value added water category contracting 8.2% for the four-week period ending April 18, 2020.”

To hear the AudioPressRelease and view the full editorial, visit http://cnw.fm/8uFWn and http://cnw.fm/6t47q

To view the full press release, visit http://cnw.fm/WrcNe

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Monday, September 28th, 2020 Uncategorized Comments Off on $WTER Featured in Exclusive Broadcast

$POAI New AI Tool Can Quickly Spot Coronavirus Outbreaks in US Counties

Researchers from Georgia Tech, Harvard Medical School and the Boston Medical Center have developed a new online learning-based tool that allows the health sector to detect coronavirus outbreaks earlier in various counties in the U.S.

The Coronavirus outbreak detection tool is usually updated 2-3 times every week. It forecasts how fast a coronavirus outbreak will spread in a county by approximating the doubling rate of cases. The doubling time refers to the total number of days it takes for the cases in any given county to double. The tool takes into consideration the reported coronavirus deaths and cases, social distancing measures, face masks mandates, the rates of positive tests, changes in tests performed as well as the CDC’s Social Vulnerability Index.

This generates an interactive map that lets the users see a specific county’s population, the total number of new coronavirus cases in the county in the last week, the average number of cases recorded every day in the last week and also the coronavirus doubling rate.

Turgay Ayer, who is an associate professor in Georgia Tech H. Milton Stewart School of Industrial and Systems Engineering, says that it is important to identify an outbreak promptly to ensure that the area in question can be isolated. This will in turn help limit the spread to neighboring locations, and this will in turn assist in effectively containing the pandemic. The tool provides an upper hand in early detection of an outbreak as it is automated, thus speeding up the process.

An assistant professor at Harvard Medical School who is also the associate director at the Massachusetts General Hospital Institute for Technology Assessment, Jagpreet Chhatwal, states that while the earlier measures focused on reducing the spread of COVID-19 at the state level, detecting outbreaks at a local level allows the legislators to execute the necessary measures at the local level. This will help in effectively containing the pandemic. The presence of the automated system helps speed up the whole process as it can detect current outbreaks within a few days.

Last week, the research team used the coronavirus outbreak tool to confirm an outbreak in Johnson County, Iowa. The outbreak is thought to have originated from the University of Iowa. Furthermore, the tool also pointed out a few counties where outbreaks might occur. These include Wheeler County in Georgia, Whitman County in Washington, Harrisonburg County in Virginia and Monroe County in Indiana.

Analysts say the use of artificial intelligence (“AI”) to detect or deal with major disease conditions isn’t very new to many players in the biomedical field, such as Predictive Oncology (NASDAQ: POAI), so it isn’t hard to see how hugely useful the COVID-19 outbreak detection tool can be at this time.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, September 28th, 2020 Uncategorized Comments Off on $POAI New AI Tool Can Quickly Spot Coronavirus Outbreaks in US Counties

$ICLK Announces Launch of One-Stop Solution – iNsights

iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced the launch of its flagship marketing analysis tool, iNsights, which gives brands in-depth and actionable consumer behavior insights to drive more effective marketing campaigns. According to the update, iNsights is an efficient one-stop solution that tracks and analyzes cross-channel campaigns covering China and overseas markets. “iNsights effectively addresses the difficulties presented to marketers by the shallow insights provided by raw data and selective sampling data analysis, as well as the inconvenience and incomparability of multiple tracking systems for different regions,” said Frankie Ho, president of International Business at iClick, in the news release. “Our recent update of iAudience and the launch of iActivate and iNsights are part of iClick’s commitment to continually build up and develop the best full-stack solutions for global marketers. iClick has always devoted itself to helping brands gain a better and deeper understanding of markets in real time and to creating the best marketing strategies driven by data and advanced algorithms.”

To view the full press release, visit http://nnw.fm/gjuKj

About iClick Interactive Asia Group Limited

iClick Interactive Asia Group is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide, including Asia and Europe.

For more information, please visit ir.i-Click.com.

NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://nnw.fm/ICLK

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Monday, September 28th, 2020 Uncategorized Comments Off on $ICLK Announces Launch of One-Stop Solution – iNsights

$UUUU The US Pledges to Help Colombia Develop Mining Sector

Mike Pompeo, the U.S. Secretary of State, made it known recently that his office would be launching a program that will provide Colombia’s mining industry with the assistance needed for its development.

On the visit to Colombia, the Secretary of State revealed that the proposal would be organized by the Department of State Energy Governance and Capacity Initiative.

In a press conference that was held at the Presidential Palace last Saturday, Pompeo told Iván Duque, Colombia’s president, that American and Colombian companies could do a lot of good together, what with the welcoming investment atmosphere and good governance, fair and open relationships and transparent rules. The companies, he said, could provide good employment opportunities.

The project will begin by evaluating the mining industry of Colombia to see how it’s doing while comparing it to the mining industries of other countries in the area. After this, the next step will be to review the regulatory and legal framework of the country and figure out ways to make the framework more competitive. Additionally, the project will also assess the regulations governing the country’s copper mining sector as well as its environmental sustainability, with a focus on the best ways to store mine tailings.

Once the coronavirus pandemic ends, Colombia will be launching 33 energy and mining projects. It is expected that these projects will generate more than 50,000 employment opportunities and rake in roughly $9.6 million in terms of investments.

In a media statement, Diego Mesa, Colombia’s mining minister, said that the United States government was a tactical partner that would help enhance the sustainable recovery of the mining and energy sectors through the fulfillment of the America Grows Initiative. He added that the Colombian mining sector had been liaising with the U.S. government through USAID to help encourage the formalization of artisanal miners.

Legal Gold, which is a USAID program, helps make illegal mines legal and minimizes mercury use in gold mining operations while also calling for the implementation of zero mercury technologies.

In the fight against illegal mining, the Colombian Ministry of Mines and Energy receives support through a State Department agreement that allows land packages to be monitored when there is evidence of alluvial gold exploitation.

Coincidentally, the minister added that the U.S. Labor Department had helped Colombia to improve the working conditions in small scale gold and coal mining operations and also eradicate child labor in the mining sector.

This planned cooperation is likely to bring trickle-down benefits to the mining sector, including companies like Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR).

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Monday, September 28th, 2020 Uncategorized Comments Off on $UUUU The US Pledges to Help Colombia Develop Mining Sector

$UUUU Awarded Funds by DOE to Develop Design for REE Production

  • Company awarded government grant that could total $1.45 million to develop design for production of rare earth elements
  • UUUU excited to play role in effort to develop domestic sources of rare earth production
  • Energy Fuels announced entry into REE sector earlier this year, ideal complement to company’s other rare earth initiatives

Energy Fuels (TSX: EFR) (NYSE American: UUUU), a leading producer of uranium in the United States, along with a team from Penn State University has been awarded a government grant for an initial amount of $150,000 to develop a design for the production of rare earth elements (“REE”) from coal-based resources (https://ibn.fm/kMbwJ). The contract was awarded by the U.S. Department of Energy (“DOE”) Office of Fossil Energy (“FE”) and the National Energy Technology Laboratory (“NETL”). If Energy Fuels is successful at the conceptual design phase, the DOE could award Energy Fuels an additional $1.3 million to complete a feasibility study.

“We are excited to have the opportunity to work with the DOE office of Fossil Energy, the National Energy Technology Laboratory, and Penn State on this important rare earth initiative,” said Energy Fuels president and CEO Mark S. Chalmers. “Energy Fuels has been carrying out substantial work over the past year to explore the potential for implementing a commercial rare earth recovery and processing program at our White Mesa Mill. This initiative to produce REOs from coal-based resources is complementary to our ongoing efforts and will potentially broaden the sources of REE feedstock available to us in the future. We also hope this project opens the door for us to work with the DOE and other agencies on future rare earth initiatives.”

The contract calls for Energy Fuels and a team of experts from Penn State to evaluate and develop a conceptual design to allow for the commercial production of mixed rare earth oxides from coal-based resources in an environmentally benign fashion. In addition, the contract also notes that DOE may award Energy Fuels a contract for the completion of a feasibility study on this initiative.

The DOE has already demonstrated the technical feasibility of extracting rare earth elements from coal and coal-based resources, but the department is looking to fast-track the advancement of commercially viable technologies to produce REEs from coal-based resources, including coal refuse, over/under burden materials, power generation ash and others.

Earlier this year, Energy Fuels announced its entry into the REE sector, noting that it believes its fully licensed and constructed White Mesa Mill could play a key role in bringing the REE supply chain back to the U.S. from China (https://ibn.fm/UEB25). The company applied for the DOE/NETL grant in June, in part because the REE minerals contained in these coal-based resources are similar to the REE minerals contained in other materials UUUU is evaluating as part of its REE program.

The contract provides initial funding for Energy Fuels and the Penn State team to complete a detailed conceptual design and flowsheet for the possible commercial operation of a facility that produces REOs from coal-based resources. Once that is complete, the DOE will determine whether to provide additional funding for the development of a feasibility study. It is also possible that the DOE could participate in the funding of a facility that performs this work.

“Rare earths are used in a host of advanced and everyday technologies, including cell phones, computers, renewable energy generation, batteries, automobiles, and military applications,” said Chalmers. “However, the U.S. does not currently have a fully integrated rare earth supply chain. Therefore, the government has made it a priority to assist in the development of domestic sources of rare earth production. With this award, we are excited to play a role in this effort, while also pursuing our other complementary rare earth initiatives. We also hope this DOE program puts Energy Fuels on the radar for other U.S. government rare earth initiatives.”

Based in Lakewood, Colorado, Energy Fuels holds three of America’s key uranium production centers: the Nichols Ranch (ISR) project in Wyoming, the Alta Mesa ISR Project in Texas and the White Mesa Mill in Utah – the only conventional uranium mill operating in the United States today. Together, these facilities have a licensed capacity of more than 11.5 million pounds of U3O8 per year. With an asset portfolio that boasts more uranium production facilities, in-ground resources, production capacity and experienced personnel than any other producer, Energy Fuels is in a unique position to maintain its position as the leading producer of uranium in an era of viable transformation of the U.S. nuclear industry.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Monday, September 28th, 2020 Uncategorized Comments Off on $UUUU Awarded Funds by DOE to Develop Design for REE Production

$CNSP Wearable Device May Help EMTs Evaluate Hemorrhaging and Save Lives

Medical technicians, room physicians and military medics may be better equipped to treat victims of gunshot wounds, battlefield injuries and vehicular accidents thanks to a new device that is in the works. The device can evaluate the effects of hemorrhage on an individual.

The research team currently working on the device development have demonstrated that the device could accurately evaluate blood loss through the measurement of seismic vibrations in an individuals’ thoracic cavity and also by detecting the changes in an individual’s heartbeat.

Associate professor in the School of Electrical and Computer Engineering at the Georgia Institute of Technology, Omer Inan, says that the team wants to develop a device that can be placed on an individual’s chest to determine if the patient is showing any signs that could indicate aggravated performance of their cardiovascular system as a result of bleeding.

The research was published in the Science Advances journal on July 22 and included partners from various institutions such as the University of Maryland. This research was also supported by the Office of Naval Research.

As most of us may not know, blood loss may be caused by various traumas. However, hemorrhage may not present as it should which may lead to it being overlooked by doctors and first responders. People who are going through trauma normally have elevated heartrates. However, blood pressure may sometimes remain stable till blood loss reaches a critical and fatal stage, which makes it harder for first responders to treat the individual.

Having a reliable medical device that can be used to noninvasively measure an injury and help responders triage victims correctly could go a long way in saving lives.

Jacob Kimball and Jonathan Zia, who are graduate students and Inan, used animal models to study electrical signals from the heart and seismic vibrations from the thoracic cavity as the blood volume reduced gradually. The researchers’ objective was to assess the signs of the performance of the cardiovascular system that could be measured externally then compare them with the information being provided by the catheters taking blood pressure and volume measurements.

They found that a seismocardiogram was the major indicator. However, the researchers noted that as the blood volume reduced, the timing of the heart’s activity changed, thus providing another cause of a weakened cardiovascular system.

The envisioned device will combine electrical and noninvasive mechanical measures to see how critical an individual’s blood loss is. An indicator on the device would also show the general condition of the individual’s cardiovascular system and how far the system is from collapsing. In the long-term, the team would like to carry out studies on humans and see how the device performs in real time.

This potentially life-saving invention is likely to attract attention from the entire biomedical field, including companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, September 28th, 2020 Uncategorized Comments Off on $CNSP Wearable Device May Help EMTs Evaluate Hemorrhaging and Save Lives

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.

The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.

XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.

Business Strategy & Milestones for 2021

On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”

In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:

  • Commercialization of infectious disease diagnostics
  • Clinical validation of transdermal and sublingual drug formulations
  • Continued investment and development in psychedelic medicine

“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”

Infectious Disease Diagnostics

XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.

Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (CE-IVD) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.

In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.

XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Drug Formulation & Delivery

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:

  • Rotigotine transdermal patch for Parkinson’s disease
  • CBD oral/sublingual strip for treatment resistant epilepsy
  • THC oral/sublingual strip for anorexia/nausea
  • CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity

Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”

Psychedelic Medicine

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:

  • An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
  • An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others

XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.

Management Team

Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.

Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.

Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.

Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.

Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.

Investment Considerations

  • XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities.
  • The company has research and development operations in North America and Europe and an operational focus in Germany.
  • XPhyto’s operations are concentrated into three core divisions: infectious disease diagnostics, clinical development of transdermal and sublingual drug formulations, and psychedelic medicine.
  • The company’s lead diagnostic product is an accurate, rapid and highly portable PCR diagnostic test system being evaluated in Europe for the detection of COVID-19.
  • XPhyto’s German subsidiary, Vektor Pharma TF GmbH, is advancing four therapeutic programs targeting neurological indications; the company intends to complete human pilot studies evaluating these products in 2021.
  • The company has two agreements in place focused on psychedelic compounds, a promising new class of API with strong potential for the treatment of mental health conditions.


Monday, September 28th, 2020 Featured Stocks Comments Off on XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

  • Adjustment Disorder with Anxiety
  • Generalized Anxiety Disorder
  • Postpartum Anxiety
  • Perioperative Anxiety
  • Panic Disorder
  • PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

  • Postpartum Depression
  • Treatment-resistant Depression
  • Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

  • Major Depressive Disorder
  • Neuropathic Pain
  • Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
  • Epilepsy
  • Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

Investment Considerations

  • VistaGen’s product portfolio consists of three novel drug candidates that, together, target multiple anxiety disorders, depression disorders and neurological disorders.
  • Two of the company’s drug candidates have received an FDA fast track designation, including for the treatment of social anxiety disorder, major depressive disorder and neuropathic pain.
  • The global CNS therapeutics market is estimated to reach $130 billion by 2025.
  • The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year.
  • VistaGen is committed to developing and commercializing multiple new generation medications that go beyond the standard of care in large markets for treatment of anxiety, depression and other central nervous system (CNS) disorders, potentially addressing the unmet needs of millions worldwide.
  • The company’s efforts are advanced by a skilled management team with decades of experience in biotechnology, pharmaceuticals, CNS drug development and more.


Monday, September 28th, 2020 Featured Stocks Comments Off on VistaGen Therapeutics Inc. (NASDAQ: VTGN)